| 1 |
28869453 | Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3. | 2017 Aug 23 |
6 |
| 2 |
26579531 | Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. | 2015 |
1 |
| 3 |
24370033 | [Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma]. | 2013 Dec |
2 |
| 4 |
22101248 | Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration. | 2012 Feb |
5 |
| 5 |
21569702 | [Effect of different regimens on bone disease of multiple myeloma]. | 2011 Apr |
1 |
| 6 |
18394701 | Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. | 2008 Nov |
1 |
| 7 |
17611556 | The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. | 2007 Sep |
1 |
| 8 |
17107351 | Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. | 2006 Dec |
1 |